Efficient Biocatalytic Synthesis of Dihalogenated Purine Nucleoside Analogues Applying Thermodynamic Calculations. 2020

Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
Chair of Bioprocess Engineering, Faculty III Process Sciences, Institute of Biotechnology, Technische Universität Berlin, Straße des 17. Juni 135, 10623 Berlin, Germany.

The enzymatic synthesis of nucleoside analogues has been shown to be a sustainable and efficient alternative to chemical synthesis routes. In this study, dihalogenated nucleoside analogues were produced by thermostable nucleoside phosphorylases in transglycosylation reactions using uridine or thymidine as sugar donors. Prior to the enzymatic process, ideal maximum product yields were calculated after the determination of equilibrium constants through monitoring the equilibrium conversion in analytical-scale reactions. Equilibrium constants for dihalogenated nucleosides were comparable to known purine nucleosides, ranging between 0.071 and 0.081. To achieve 90% product yield in the enzymatic process, an approximately five-fold excess of sugar donor was needed. Nucleoside analogues were purified by semi-preparative HPLC, and yields of purified product were approximately 50% for all target compounds. To evaluate the impact of halogen atoms in positions 2 and 6 on the antiproliferative activity in leukemic cell lines, the cytotoxic potential of dihalogenated nucleoside analogues was studied in the leukemic cell line HL-60. Interestingly, the inhibition of HL-60 cells with dihalogenated nucleoside analogues was substantially lower than with monohalogenated cladribine, which is known to show high antiproliferative activity. Taken together, we demonstrate that thermodynamic calculations and small-scale experiments can be used to produce nucleoside analogues with high yields and purity on larger scales. The procedure can be used for the generation of new libraries of nucleoside analogues for screening experiments or to replace the chemical synthesis routes of marketed nucleoside drugs by enzymatic processes.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D010430 Pentosyltransferases Enzymes of the transferase class that catalyze the transfer of a pentose group from one compound to another.
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006846 Hydrocarbons, Halogenated Hydrocarbon compounds with one or more HYDROGEN atoms substituted with HALOGENS. Halogenated Hydrocarbons
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell

Related Publications

Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
April 2022, Expert opinion on drug discovery,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
June 1981, Biochemistry,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
December 1996, Hematology and cell therapy,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
May 1987, Journal of medicinal chemistry,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
July 2018, MedChemComm,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
December 2019, Molecules (Basel, Switzerland),
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
November 2003, Journal of medicinal chemistry,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
January 1994, Drugs,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
June 2008, Recent patents on anti-cancer drug discovery,
Heba Yehia, and Sarah Westarp, and Viola Röhrs, and Felix Kaspar, and Robert T Giessmann, and Hendrik F T Klare, and Katharina Paulick, and Peter Neubauer, and Jens Kurreck, and Anke Wagner
October 2003, Angewandte Chemie (International ed. in English),
Copied contents to your clipboard!